Aripiprazole Solution
Product Images NDC 62135-904

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 62135-904). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

"image Description" (Aripiprazole Oral Solution 150ml Bottle Label)

Label for Aripiprazole Oral Solution 1 mg/mL by Chartwell RX, LLC, containing 150 mL. The label includes storage instructions, pharmacist dispensing guidance, the NDC number 62135-904-51, and a barcode. The product is a prescription oral solution.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 1)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing fold changes in AUC and Cmax of Aripiprazole relative to a reference without interacting drug. The graph plots effects of CYP3A4 inhibitor (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blocker (famotidine), and other drugs (valproate, lithium, lorazepam). Error bars indicate variability for each drug interaction.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 2)

A scatter plot showing the fold change and 90% confidence intervals for dehydro-aripiprazole pharmacokinetic parameters (AUC and Cmax) relative to reference without interacting drug. The x-axis represents change relative to reference (0.5 to 3.0), and the y-axis lists interacting drugs grouped by CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 3)

A forest plot showing fold change and 90% confidence intervals of pharmacokinetic parameters (AUC, Cmax, INR, DMDRP) for various drugs (including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram) relative to a reference without an interacting drug. The x-axis measures change relative to reference from 0.5 to 3.0.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 4)

A chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic fold changes in AUC and Cmax relative to reference for special populations. Variables include CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment, with horizontal error bars representing 90% confidence intervals.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 5)

A pharmacokinetic chart showing the fold change and 90% confidence interval for Dehydro-Aripiprazole exposure (AUC and Cmax) relative to reference across different factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents the change relative to reference, and data points indicate variability in these pharmacokinetic parameters.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 6)

A Kaplan-Meier curve depicting the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole (solid blue line) and placebo (dashed red line). The graph includes a table showing the number of subjects at risk for each group at various time points.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 7)

A Kaplan-Meier curve showing the proportion of subjects with relapse over days from randomization. The graph compares Aripiprazole (blue solid line) and Placebo (red dashed line) with a table below indicating the number of subjects at risk for each group at various time points up to 182 days.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 8)

A Kaplan-Meier curve displaying the proportion of subjects with relapse over days from randomization. Two groups are compared: Aripiprazole (solid blue line) and Placebo (dashed red line). The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Below the graph, the number of subjects at risk is tabulated over time for each group.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Graph 9)

A line graph showing least-squares mean change in YGTSS total tic score from baseline over weeks of treatment. It compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, across an 8-week period. The y-axis represents change in tic score, with decreasing values indicating improvement.*

FDA Label Image

"image Description" (Aripiprazole Oral Solution Structure)

Chemical structure depicting the active ingredient Aripiprazole, showing its molecular connectivity including chlorinated phenyl rings, piperazine groups, and other characteristic chemical bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.